As of June 21, 2025, Antibe Therapeutics Inc (ATE.TO) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Antibe Therapeutics Inc's Forward P/E to Peers
To better understand Antibe Therapeutics Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Antibe Therapeutics Inc (ATE.TO) | - |
| CorMedix Inc (CRMD) | 16.68 |
| Agile Therapeutics Inc (AGRX) | 0.76 |
Compared to its competitors, Antibe Therapeutics Inc's Forward P/E is difficult to compare due to insufficient data.